Cancer therapeutic antibodies come of age: Targeting minimal residual disease

Molecular Oncology

Volumn 1, Issue 1, 2007, Pages 42-54

  Ben Kasus, Tsipi ^a   Schechter, Bilha ^a   Sela, Michael ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antibody; Cancer; CD20; Cytotoxicity; Hybridoma; Therapy

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CHIMERIC ANTIBODY; DACLIZUMAB; DENOSUMAB; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN LMB2; IPILIMUMAB; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY G250; OREGOVOMAB; PACLITAXEL; PANITUMUMAB; PEMTUMOMAB; PEPTIDE ANTIBODY; PERTUZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAMYL ZENAPAX; ZANOLIMUMAB;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TARGETING; GENETIC ENGINEERING; HEAD AND NECK CANCER; HUMAN; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM, RESIDUAL;

EID: 34248641115     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2007.01.003     Document Type: Review

References (105)

1. Aboud-Pirak E., Hurwitz E., Pirak M.E., Bellot F., Schlessinger J., and Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst. 80 (1988) 1605-1611
2. Andrechek E.R., and Muller W.J. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2 (2000) 211-216
3. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., Klumperman J., and Scheller R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell. 15 (2004) 5268-5282
4. Balzar M., Winter M.J., de Boer C.J., and Litvinov S.V. The biology of the 17-1A antigen (Ep-CAM). J Mol. Med. 77 (1999) 699-712
5. Bargmann C.I., Hung M.C., and Weinberg R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45 (1986) 649-657
6. Baselga J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14 (1996) 737-744
7. Baselga J., Perez E.A., Pienkowski T., and Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 Suppl. 1 (2006) 4-12
8. Beerli R.R., Wels W., and Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269 (1994) 23931-23936
9. Bell R. What can we learn from Herceptin trials in metastatic breast cancer?. Oncology 63 (2002) 39-46
10. Bezombes C., Grazide S., Garret C., Fabre C., Quillet-Mary A., Muller S., Jaffrezou J.P., and Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104 (2004) 1166-1173
11. Bober L.A., Grace M.J., Pugliese-Sivo C., Rojas-Triana A., Waters T., Sullivan L.M., and Narula S.K. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology 29 (1995) 111-119
12. Bonavida B., and Vega M.I. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist. Updat. 8 (2005) 27-41
13. Bonner J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
14. Boulianne G.L., Hozumi N., and Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 312 (1984) 643-646
15. 2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121 (1993) 1121-1132
16. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H.J., and Goldenberg D.M. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol. 44 (2007) 1331-1341
17. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
18. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney Jr. D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
19. Christianson T.A., Doherty J.K., Lin Y.J., Ramsey E.E., Holmes R., Keenan E.J., and Clinton G.M. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58 (1998) 5123-5129
20. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7 (2006) 505-516
21. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
22. Cobleigh M.A., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1999) 2639-2648
23. Cragg M.S., Walshe C.A., Ivanov A.O., and Glennie M.J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8 (2005) 140-174
24. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., Dennis P.A., and Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61 (2001) 4892-4900
25. Deans J.P., Li H., and Polyak M.J. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107 (2002) 176-182
26. Di Gaetano N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581-1587
27. Dijoseph J.F., Dougher M.M., Armellino D.C., Kalyandrug L., Kunz A., Boghaert E.R., Hamann P.R., and Dmale N.K. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol. Immunother. (2006) [Epub ahead of print]
28. Drebin J.A., Link V.C., Weinberg R.A., and Greene M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 9129-9133
29. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., and Moore M.W. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124 (1997) 4999-5011
30. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl. 3 (2005) 11-16
31. Fishwild D.M., et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14 (1996) 845-851
32. Flanagan J.G., and Leder P. neu proto-oncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 8057-8061
33. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., Sela M., and Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1915-1920
34. Garrett T.P., et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cells. 11 (2003) 495-505
35. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., and Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378 (1995) 390-394
36. Gill G.N., Kawamoto T., Cochet C., Le A., Sato J.D., Masui H., McLeod C., and Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259 (1984) 7755-7760
37. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., Rambaldi A., and Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
38. Griffiths A.D., et al. Human anti-self antibodies with high specificity from phage display libraries. Embo. J. 12 (1993) 725-734
39. Harris N.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
40. Hofmeister J.K., Cooney D., and Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26 (2000) 133-143
41. Hong F., et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173 (2004) 797-806
42. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59 (1999) 1935-1940
43. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., and Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9 (1989) 1165-1172
44. Hurwitz E., Stancovski I., Sela M., and Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Nat. Acad. Sci. U. S. A. 92 (1995) 3353-3357
45. Iannello A., and Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 24 (2005) 487-499
46. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
47. Janas E., Priest R., Wilde J.I., White J.H., and Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139 (2005) 439-446
48. Joensuu H., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354 (2006) 809-820
49. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., and Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4995-5000
50. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
51. Konecny G., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst. 95 (2003) 142-153
52. Lane H.A., Motoyama A.B., Beuvink I., and Hynes N.E. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann. Oncol. 12 (2001) S21-S22
53. Lopes de Menezes D.E., et al. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J. Immunother. 30 (2007) 64-74
54. Lu D., Shen J., Vil M.D., Zhang H., Jimenez X., Bohlen P., Witte L., and Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278 (2003) 43496-43507
55. Maier L.A., Xu F.J., Hester S., Boyer C.M., McKenzie S., Bruskin A.M., Argon Y., and Bast Jr. R.C. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res. 51 (1991) 5361-5369
56. Marches R., and Uhr J.W. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int. J. Cancer 112 (2004) 492-501
57. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., and Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 (1991) 581-597
58. Marmor M.D., and Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23 (2004) 2057-2070
59. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27 (2000) 46-52 (discussion, pp. 92-100)
60. McKenzie S.J., Marks P.J., Lam T., Morgan J., Panicali D.L., Trimpe K.L., and Carney W.P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4 (1989) 543-548
61. McLaughlin P., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
62. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
63. Mendez M.J., et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15 (1997) 146-156
64. Modak S., Koehne G., Vickers A., O'Reilly R.J., and Cheung N.K. Rituximab therapy of lymphoma is enhanced by orally administered (1->3),(1->4)-d-beta-glucan. Leuk. Res. 29 (2005) 679-683
65. Mohsin S.K., et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 23 (2005) 2460-2468
66. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61 (2001) 4744-4749
67. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 6851-6855
68. Nagata Y., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
69. Neve R.M., Nielsen U.B., Kirpotin D.B., Poul M.A., Marks J.D., and Benz C.C. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Commun. 280 (2001) 274-279
70. Nicholson K.M., Streuli C.H., and Anderson N.G. Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res. Treat. 81 (2003) 117-128
71. Nimmerjahn F., Bruhns P., Horiuchi K., and Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
72. O'Keefe T.L., Williams G.T., Davies S.L., and Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics 48 (1998) 125-132
73. Olivieri A., et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol. Blood Marrow Transplant 11 (2005) 627-636
74. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., and Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99 (2002) 1314-1319
75. Pegram M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 (1999) 2241-2251
76. Pegram M.D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16 (1998) 2659-2671 0732-183x
77. Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., and Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56 (1996) 3666-3669
78. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., and Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151 (1997) 1523-1530
79. Piccart-Gebhart M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
80. Polyak M.J., and Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99 (2002) 3256-3562
81. Polyak M.J., Tailor S.H., and Deans J.P. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J. Immunol. 161 (1998) 3242-3248
82. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
83. Pulczynski S., Boesen A.M., and Jensen O.M. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - an immunofluorescence and immunoelectron microscopy study. Leuk. Res. 18 (1994) 541-552
84. Ravetch J.V., and Lanier L.L. Immune inhibitory receptors. Science 290 (2000) 84-89
85. Riechmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
86. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G.R., and Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389 (1997) 725-730
87. Romond E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
88. Ross J.S., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
89. Saaristo A., Karpanen T., and Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 (2000) 6122-6129
90. Skvortsova I., Skvortsov S., Popper B.A., Haidenberger A., Saurer M., Gunkel A.R., Zwierzina H., and Lukas P. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J. Radiat. Res. (Tokyo) 47 (2006) 183-196
91. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
92. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
93. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res. Treat. 94 Suppl. 1 (2005) S5
94. Spiridon C.I., Ghetie M.A., Uhr J., Marches R., Li J.L., Shen G.L., and Vitetta E.S. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer. Res. 8 (2002) 1720-1730
95. Spiridon C.I., Guinn S., and Vitetta E.S. A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin. Cancer Res. 10 (2004) 3542-3551
96. Stancovski I., Hurwitz E., Leitner O., Ullrich A., Yarden Y., and Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8691-8695
97. Stein R., Belisle E., Hansen H.J., and Goldenberg D.M. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol. Immunother. 37 (1993) 293-298
98. Sulis M.L., and Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 13 (2003) 478-483
99. Tuscano J.M., O'Donnell R.T., Miers L.A., Kroger L.A., Kukis D.L., Lamborn K.R., Tedder T.F., and DeNardo G.L. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 101 (2003) 3641-3647
100. Valabrega G., et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24 (2005) 3002-3010
101. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., and Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12 (2006) 4027-4035
102. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A., and Fisher R.I. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma 46 (2005) 1569-1573
103. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
104. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G., and Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59 (1999) 1236-1243
105. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 2569-2573